The CAR T cells secrete PD-1 nanobodies that block PD-1/PD-L1 signaling to boost T‑cell activity, but they do not target or kill PD‑1–expressing cells; killing is directed against mesothelin-positive tumor cells via CAR-mediated cytolysis.